Synairgen Plc – Strategy, SWOT and Corporate Finance Report

Synairgen Plc – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company

Key Highlights

Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-ß/SNG001) for chronic obstructive pulmonary disease (COPD) in Phase II trial; The company develops drugs based on BioBank platform technology. Its BioBank comprises blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma and COPD. The company uses these resources to develop in vitro and ex vivo models, which can be used for discovering novel drug targets. It discovers and develops the drug targets through early stages and out-licenses them to other pharmaceutical companies for further development and manufacturing. Synairgen is headquartered at Southampton, the UK.

Scope

Detailed information on Synairgen Plc required for business and competitor intelligence needs

A study of the major internal and external factors affecting Synairgen Plc in the form of a SWOT analysis

An in-depth view of the business model of Synairgen Plc including a breakdown and examination of key business segments

News about Synairgen Plc, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of Synairgen Plc and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Synairgen Plc as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Synairgen Plcs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Verona Pharma Plc

Theravance Biopharma Inc

Oxagen Ltd

Novartis AG

Napp Pharmaceuticals Ltd

GlaxoSmithKline Plc

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Synairgen Plc - Key Facts

Synairgen Plc - Key Employees

Synairgen Plc - Key Employee Biographies

Synairgen Plc - Major Products and Services

Synairgen Plc - History

Synairgen Plc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 Company Analysis

Company Overview

Synairgen Plc - Business Description

R&D Overview

Synairgen Plc - SWOT Analysis

SWOT Analysis - Overview

Synairgen Plc - Strengths

Synairgen Plc - Weaknesses

Synairgen Plc - Opportunities

Synairgen Plc - Threats

Synairgen Plc - Key Competitors

Section 3 Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 Company’s Lifesciences Financial Deals and Alliances

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Synairgen Plc, Recent Deals Summary

Section 5 Company’s Recent Developments

Sep 30, 2019: Synairgen: Interim results for the six months ended 30 June 2019

Apr 18, 2019: Synairgen: Directorate change, posting of annual report, and notice of AGM

Feb 25, 2019: Synairgen: Preliminary statement of results for the year ended 31 December 2018

Jan 17, 2019: Synairgen announces positive progress on LOXL2 programme by Pharmaxis

Sep 25, 2018: Synairgen: Interim results for the six months ended 30 June 2018

Mar 15, 2018: Synairgen: Preliminary statement of results for the year ended 31 December 2017

Section 6 Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

Synairgen Plc, Key Facts

Synairgen Plc, Key Employees

Synairgen Plc, Key Employee Biographies

Synairgen Plc, Major Products and Services

Synairgen Plc, History

Synairgen Plc, Subsidiaries

Synairgen Plc, Key Competitors

Synairgen Plc, Ratios based on current share price

Synairgen Plc, Annual Ratios

Synairgen Plc, Annual Ratios (Cont…1)

Synairgen Plc, Interim Ratios

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Synairgen Plc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Synairgen Plc, Performance Chart (2014 – 2018)

Synairgen Plc, Ratio Charts

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Synairgen Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports